Bone Biopsy Market By Product Type (Bone Biopsy Needles, Core Sampling Devices, Coaxial Access Systems, Powered Biopsy Systems, Sterile Procedure Kits, Specimen Retrieval Accessories); By Procedure Type (Needle Biopsy, Surgical Biopsy); By End User (Hospitals, Diagnostic Clinics, Research Institutes, Contract Research Organizations [CROs]); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Bone Biopsy Market: Image-Guided Procedures, Outpatient Reimbursement, and Recurring Consumables Support Market Expansion

The Global Bone Biopsy Market was valued at USD 230.68 billion in 2025 and is projected to reach USD 349.15 billion by 2032, expanding at a CAGR of 6.1%, according to Strategic Market Research.

 

The market covers bone lesion and bone marrow biopsy needles, core-sampling devices, coaxial access systems, powered biopsy drivers, sterile procedure kits, aspiration accessories, specimen-retrieval components, and related disposables. Demand is concentrated in interventional radiology, orthopedic oncology, hematology, infectious disease, nephrology, and pathology departments.

 

Bone-tissue and bone-marrow biopsies are clinically distinct but commercially linked. Bone-tissue biopsy is used to assess structural lesions, tumors, infections, or unexplained bone damage. Bone-marrow biopsy is mainly used for leukemia, lymphoma, multiple myeloma, blood disorders, treatment monitoring, and cancer staging. Manufacturers often support both procedures through common needle platforms, powered access systems, sterile kits, distribution channels, and hospital purchasing agreements.

 

Percutaneous Core Biopsy Is Replacing Many Open Procedures

The most important change in the market is the shift from open surgical biopsy toward percutaneous core needle biopsy. Open biopsy remains necessary when a larger specimen is required, when an earlier needle biopsy is inconclusive, or when the biopsy route must be coordinated with planned tumor surgery. However, open procedures generally require more operating-room resources, a larger incision, anesthesia support, and longer recovery.

CT-guided biopsy has become the preferred approach for many deep bone lesions because it enables accurate localization while helping clinicians avoid nearby organs, nerves, and blood vessels. Published studies report diagnostic accuracy of up to 94% for CT-guided bone biopsy, although results vary by lesion type, anatomical location, tissue quality, and pathology expertise.

Ultrasound guidance can provide high diagnostic yield in accessible lesions and may reduce radiation exposure and procedure cost, but it is less suitable for deep spinal or fully intraosseous targets.

Reported diagnostic accuracy ranges from roughly 66% to 99% across published studies. This variation reflects differences in patient selection, lesion visibility, bone density, sample size, operator experience, and whether the lesion is lytic or sclerotic. A single accuracy figure should therefore not be applied to every biopsy system or clinical setting.

The commercial value of percutaneous biopsy extends beyond the needle itself. Hospitals can perform many procedures in outpatient radiology departments or day-care settings, reducing operating-room use and shortening patient recovery.

Clinical literature has reported complication rates below 2% for many image-guided procedures, while open biopsy carries higher risks of infection, bleeding, wound complications, and hospitalization. This economic and clinical advantage supports recurring demand for needles, coaxial introducers, sterile trays, local-anesthesia supplies, specimen containers, and imaging-compatible accessories.

 

Cancer Demand Extends Beyond Primary Bone Tumors

Primary bone and joint cancers are rare. SEER reports an age-adjusted U.S. incidence rate of approximately 1.1 cases per 100,000 people and an estimated 4,110 new cases in 2026. Primary bone cancer alone therefore cannot support the full commercial value attributed to the market.

A larger share of demand comes from suspected metastatic disease, unexplained skeletal lesions, vertebral abnormalities, marrow disorders, and cancer staging. Bone is a common site of metastatic spread, particularly in breast, prostate, lung, kidney, and thyroid cancers.

Tissue sampling may be required when imaging cannot confirm the origin of a lesion, when molecular or receptor testing could change treatment, or when a new skeletal abnormality may represent either cancer progression or another disease.

Biopsy planning is especially important in suspected primary bone tumors. Poor placement of the biopsy tract can complicate later surgery or reduce the feasibility of limb-sparing treatment. Complex cases are therefore concentrated in specialist orthopedic-oncology and cancer centers rather than distributed evenly across all hospitals.

The United States has nearly 1,400 Commission on Cancer-accredited hospitals and cancer centers. These institutions form an identifiable customer base for biopsy systems, interventional-radiology equipment, pathology services, and oncology procedure kits. Their multidisciplinary structure also increases demand for devices that can obtain sufficient tissue for histology, immunohistochemistry, and molecular analysis.

 

Osteomyelitis Is an Important Underused Application

Bone biopsy is also used to diagnose osteomyelitis, including diabetic foot infection and vertebral infection. A properly collected bone sample can identify the responsible organism and support targeted antibiotic therapy when superficial tissue cultures are unreliable.

A systematic review of percutaneous bone biopsy for diabetic foot osteomyelitis included 837 biopsies among 780 patients and reported a pooled culture-positive rate of 84%. The result indicates strong diagnostic potential, although safety reporting, antibiotic changes, and long-term outcomes were inconsistent across the included studies.

Clinical guidelines recommend obtaining bone rather than soft tissue when a microbiological diagnosis of diabetic foot osteomyelitis is required. Despite this, real-world adoption remains limited by access to trained operators, imaging capacity, pathology and microbiology support, procedural cost, and the continued use of empirical antibiotic treatment.

This creates a commercial opportunity for manufacturers that can support reliable outpatient sampling, efficient specimen handling, and training for radiology or foot-care teams. However, demand will not expand uniformly. In vertebral osteomyelitis, reported biopsy sensitivity can be substantially lower, and a positive blood culture may remove the need for an invasive procedure.

 

U.S. Reimbursement Supports Outpatient Bone Biopsy

U.S. reimbursement confirms that bone biopsy is an established clinical service. CPT 20220 is generally used for superficial needle or trocar bone biopsy, while CPT 20225 covers deep bone biopsy at sites such as the femur or vertebral body. Imaging guidance may be reimbursed separately where appropriate.

A 2025 reimbursement guide based on CMS schedules listed approximate hospital-outpatient payment of USD 1,620 for bone biopsy and around USD 708 in an ambulatory surgical center. Physician payments were materially lower because the facility payment must cover imaging, staff, drugs, supplies, procedure-room use, pathology coordination, and other packaged costs.

This reimbursement structure places pressure on device pricing. Hospitals do not evaluate a biopsy needle in isolation; they compare its price with the total economic value of the procedure. A premium system is more likely to gain adoption when it improves specimen adequacy, reduces sampling time, performs well in hard or sclerotic bone, or lowers the risk of repeat biopsy.

CMS preliminary hospital-outpatient data from January to September 2022 recorded 3,904 claims for superficial bone biopsy and 5,383 for deep bone biopsy. The same dataset separately listed 3,682 diagnostic bone-marrow biopsy claims. These figures do not represent total U.S. procedure volume, but they demonstrate why bone-tissue and bone-marrow procedures should be counted separately.

The widely repeated claim that more than 700,000 bone or bone-marrow biopsies are performed annually in the United States also requires qualification. The figure often combines marrow aspiration, marrow biopsy, and structural bone biopsy.

MD Anderson alone reports performing around 10,000 bone-marrow biopsies annually, showing how large hematology and oncology centers can generate substantial volume. However, this institutional figure cannot be used to estimate national bone-lesion biopsy demand without adjustment.

 

Consumables Generate the Largest Recurring Revenue Pool

The market is driven mainly by consumables. Each procedure requires sterile needles, trephines, cannulas, sample traps, connectors, drapes, and specimen-handling products. Powered systems also include a reusable driver, but their commercial value depends on recurring sales of compatible single-use kits.

BD’s Trek system pairs a reusable powered driver with separate disposable kits for bone-lesion and bone-marrow procedures. Teleflex uses a similar approach with its Arrow OnControl platform, offering procedure-specific systems for marrow access, vertebral biopsy, and bone-lesion sampling.

This supports a recurring-revenue model in which driver placement generates ongoing consumable sales. The value proposition is strongest in high-volume oncology, hematology, and interventional-radiology departments, where capital costs can be spread across many procedures. Lower-volume hospitals may still favor manual needles because they require less upfront investment and typically have lower per-case acquisition costs.

Powered systems are positioned around faster access, lower manual force, and more consistent performance in dense bone. Hospitals, however, increasingly want evidence that these benefits translate into better diagnostic yield, sample quality, procedure times, or fewer repeat biopsies. Bench testing or basic regulatory equivalence alone rarely supports a significant price premium.

 

Competition Extends Beyond Powered Biopsy Platforms

Competition in the bone biopsy market extends across powered access systems, manual needles, coaxial platforms, bone-marrow aspiration products, and specimen-retrieval devices. Suppliers compete at several stages of the procedure, including cortical bone access, tissue cutting, multiple-core collection, sample retention, and specimen removal.

Becton, Dickinson and Company (BD) has a broad position across bone-lesion and bone-marrow biopsy. Its portfolio includes the reusable-driver-based BD Trek powered system, the Original Jamshidi needle, and the Jamshidi Evolve bone-marrow needle. Jamshidi Evolve is indicated for bone-marrow aspiration and core biopsy and supports the collection of multiple samples through the same access site. This gives BD exposure to both powered capital equipment and recurring disposable needle and tray revenue.

Merit Medical Systems competes through the Madison and Huntington bone biopsy systems. These products use perforating cannulas and tactile drilling rather than relying entirely on powered access. The Huntington platform offers guided access and components designed to progress through hard bone, while Merit’s wider bone-biopsy range gives interventional radiologists a choice between direct and guidewire-assisted approaches. The company positions these systems as alternatives for facilities seeking controlled bone access without purchasing a powered driver.

Siemens Healthineers markets the OmniBone powered bone biopsy system for accessing bone lesions and collecting core samples. Its entry broadens Siemens Healthineers’ interventional-oncology portfolio beyond diagnostic imaging and procedure guidance into the biopsy-device category. This combination may strengthen its position in hospitals seeking biopsy tools that can be integrated with existing image-guided oncology workflows.

Cook Medical supplies the Osteo-Site coaxial bone biopsy needle and related vertebroplasty and bone-access needle sets. The Osteo-Site system is intended for bone access, biopsy, and sample collection and can be used with compatible vertebroplasty needles. Cook’s established interventional-radiology distribution network allows the company to compete through procedure-specific needles and access products rather than a dedicated powered platform.

Medax focuses on biopsy, interventional, and specialty needles and offers an extensive bone-marrow biopsy and aspiration range. Its portfolio includes Medlock, Hemax, Medbone, Neo Oxus, Med-L, Med-B, and Med-J systems, covering aspiration, core biopsy, extraction cannulas, and multiple-sample configurations. This breadth gives Medax a stronger position in manual and disposable products, particularly in markets where hospitals prioritize procurement flexibility and lower capital requirements.

Teleflex remains an important powered-system competitor through the Arrow OnControl platform, which serves marrow access, vertebral biopsy, and bone-lesion sampling. Argon Medical supplies products such as Osty-Core bone biopsy needles, while regional manufacturers compete through hospital distributors, private-label arrangements, and public procurement contracts.

Recent FDA clearances also indicate continued product entry. Zhejiang CurasWay Medical Technology received clearance in 2025 for a bone-marrow biopsy needle. HS Hospital Service received clearance in 2024 for a single-use biopsy-sample trapping device, while SurGenTec received clearance in 2025 for a neuro-access kit capable of harvesting cancellous bone or bone-marrow core samples. BD’s Trek powered system received FDA clearance in 2022.

These approvals show that market competition is no longer limited to the biopsy needle itself. Manufacturers are targeting bone penetration, sample quality, extraction, core retention, procedural speed, and the ability to collect multiple specimens. Hospitals will nevertheless require evidence that these product differences improve diagnostic yield, reduce repeat procedures, or lower total procedure cost. FDA clearance establishes substantial equivalence to an existing device but does not independently prove clinical superiority.

 

Bone Biopsy Market Outlook

Biopsy needles and disposable kits will continue to generate the largest share of recurring revenue. Powered biopsy systems are expected to grow faster from a smaller base, particularly in high-volume centers and difficult bone-access procedures. Percutaneous core needle biopsy will remain the dominant procedure type because it supports outpatient care, lower complication rates, and reduced use of open surgery.

Oncology and hematology will remain the largest combined application group where bone-marrow biopsy is included in the market definition. Osteomyelitis represents a smaller but underused opportunity, while metabolic bone disease and renal osteodystrophy will remain specialist niches.

The market’s strongest growth drivers are the continued replacement of open diagnostic surgery with image-guided sampling, rising demand for tissue confirmation in metastatic disease, recurring sales of sterile consumables, and the need for larger, higher-quality samples for modern pathology.

Key restraints include variable diagnostic yield, limited specialist expertise, tender-based price pressure, dependence on imaging infrastructure, and inconsistent market definitions. Open surgical biopsy will also remain necessary when needle samples are inadequate or when tumor architecture requires a larger specimen.

 

Bone Biopsy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 230.68 Billion
Revenue Forecast in 2032	USD 349.15 Billion
Overall Growth Rate	CAGR of 6.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Procedure Type, By End User, By Geography
By Product Type	Bone Biopsy Needles, Core Sampling Devices, Coaxial Access Systems, Powered Biopsy Systems, Sterile Procedure Kits, Specimen Retrieval Accessories
By Procedure Type	Needle Biopsy, Surgical Biopsy
By End User	Hospitals, Diagnostic Clinics, Research Institutes, Contract Research Organizations (CROs)
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing adoption of image-guided percutaneous biopsy procedures.Increasing demand for tissue confirmation in oncology, metastatic disease assessment, and hematological disorders.Rising preference for outpatient procedures supported by recurring consumable usage and improved reimbursement pathways.
Customization Option	Available upon request